Navigation Links
Breema Center to Host International Intensive Week in Buhl, Germany
Date:4/27/2010

BUHL, Germany, April 27 /PRNewswire/ -- The Breema Center today announced an international Intensive to be held in Buhl, Germany the 12-16 of May, 2010. Breema is a common sense approach to physical, emotional and mental health that emphasizes the mind-body connection.  The Intensive program is designed to help new students get familiar with Breema and to help long time students deepen their understanding of Breema and its Nine Principles of Harmony. The intensive will be held in the Breema Seminar House in Buhl and is open to everyone, regardless of experience level with Breema.

"Participating in a Breema Intensive is a great way to study Breema, which provides a new way of looking at oneself," said Dr. Jon Schreiber, director of the Breema Center in Oakland, CA.  and author of several books on Breema. "Students are encouraged to apply the philosophy and principles to every interaction and event, so that when they are outside the classroom, they can bring more harmony and vitality to everyday life."

Breema Intensives in Buhl are an 11-year tradition, and have attracted people from across Europe and the Americas. On average, 20 Breema instructors participate at the event to teach students Breema bodywork sequences and Self-Breema exercises, which are completely integrated with the Nine Principles of Harmony that are its foundation.

Pari Schneider, a Breema Instructor in Buhl who has taught internationally for 22 years, is coordinating the Intensive with two staff instructors from the Breema Center, who will travel to Europe to participate. "It's heart-warming to see so many new a
'/>"/>

SOURCE The Breema Center
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology news :

1. SAFC(R) Announces $6.25 Million Expansion at Lenexa Center of Excellence
2. Dr. Jeremy M. Stipkala, Patent Attorney, Speaks on USC NanoCenter Panel
3. Moffitt Cancer Center: Growing interest in prognostic test for non-small cell lung cancer
4. Texas Childrens Cancer Center first in Texas to magnetically lengthen nine-year-olds leg as she grows
5. UT Southwesterns BioCenter driving biotech, medical innovation in North Texas
6. National Center for Secure and Resilient Maritime Commerce releases annual report
7. Lombardi receives $7.5 million grant for Breast Cancer Center for Cancer Systems Biology
8. Robertson Foundation donates $10.2 million for Duke Cell Therapy Center
9. Moffitt Cancer Center signs licensing agreement with Proteacel, LLC
10. Apollo Solar Energy funds new $1.5 million CdTe solar research center at NJIT
11. Center aims to cut obesity in black, Latino New Yorkers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/10/2014)... Dec. 9, 2014  Valencell, a leader in performance ... a staggering demand from its licensees for highly accurate, ... is not solely coming from fitness and health sectors, ... "A wearable is only as useful as the ... the ultimate driver in long-term mass consumer adoption of ...
(Date:12/10/2014)... , Dec. 08, 2014 Research and Markets ... addition of the "Biometrics Market in Japan ... http://photos.prnewswire.com/prnh/20130307/600769 The ... such as rural banking and upgradation of the ... witnessed in the market. Besides the aforementioned projects, ...
(Date:12/5/2014)... -- Tute Genomics, a leader in cloud-based solutions for genome ... led by UK-based Eurovestech. Peak Ventures and a number ... "We are at a pivotal time in ... seeks new approaches for the diagnosis, treatment and prevention ... and CEO of Tute Genomics. "One of the main ...
Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
... biotechnological company, has presented at the CIC ... (Derio), the first DNA chip concerning diagnosis ... the discrimination between normal, steatosis and NASH ... a progressive disease of the liver of ...
... system is a marvel of versatility, creating a variety of ... To carry out these tasks, immune cells follow a career ... a report in the May 2005 issue of Immunity, Fox ... Ph.D. and Dietmar J. Kappes, Ph.D., show that cell-receptor signaling ...
... of the National Institutes of Health, have built the ... Scientists searching for genes that go awry and cause ... point of reference because it pinpoints which genes are ... normal conditions, without known disease. , Scientists can compare ...
Cached Biology News:Owl genomics presents a HEPATOCHIP for diagnosis of non-alcoholic steatohepatitis 2Fox Chase study shows that weakened T-cell receptor signals change T-cell lineage 2Fox Chase study shows that weakened T-cell receptor signals change T-cell lineage 3Gov't Creates Gene Database of Normal Human Tissues 2Gov't Creates Gene Database of Normal Human Tissues 3Gov't Creates Gene Database of Normal Human Tissues 4
(Date:12/24/2014)... Nashville Fertility Center announced that ... the American Society for Reproductive Medicine (ASRM), a leading ... reproductive medicine. In his new role as treasurer, ... board and will have a voice in furthering the ... supported ASRM since 1984 when he joined while conducting ...
(Date:12/24/2014)... Texas , Dec. 23, 2014 ... company focused on gynecologic disease, announced today that ... Schuler , Birchview Fund LLC and several Vermillion ... of unregistered shares of Vermillion,s common stock and ... stock in a private placement.  ...
(Date:12/24/2014)... NEW YORK , Dec. 23, 2014 /PRNewswire/ ... study of mazindol in children with attention deficit/hyperactivity disorder ... December 2014 . The paper, titled ... attention deficit/hyperactivity disorder" ( Konofal et al, ... eCollection 2014 ) shows that mazindol might be ...
(Date:12/22/2014)... N.C. , Dec. 22, 2014  Alternative ... announced that it has signed a letter of ... that has developed and patented a nanotechnology-based development ... diagnostics products that enable rapid on-site collection and ... use/abuse and health issues in an immediate, non-invasive ...
Breaking Biology Technology:Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3ALNE Announces Intention To Acquire BioTechPharma 2
... Laboratories, pathologist, Ronald L. Weiss, MD, MBA, FCAP, received ... Pathologists at CAP ,11, the organization,s annual meeting, held ... the award honors members "who have made a broad ... of pathology." (Logo: http://photos.prnewswire.com/prnh/20110915/SF69370LOGO ) ...
... 2011 NewCardio, Inc., (OTC BB: NWCI) a cardiovascular ... Clinilabs, will utilize QTinno®, NewCardio,s automated cardiac safety solution, ... new drug under development for a central nervous system ... one important aspect of the trial. Clinilabs, ...
... 2011 Orexigen® Therapeutics, Inc. (Nasdaq: OREX ), ... announced financial results for the third quarter of 2011. For ... net loss of $4.6 million, or $0.10 per share, as ... per share, for the third quarter of 2010. As of ...
Cached Biology Technology:ARUP Laboratories' Pathologist, Ronald L. Weiss, MD, Honored With Lifetime Achievement Award for Contributions to Patient Care and Pathology 2Clinilabs will Conduct Phase 1 Trial Using QTinno® 2Clinilabs will Conduct Phase 1 Trial Using QTinno® 3Clinilabs will Conduct Phase 1 Trial Using QTinno® 4Clinilabs will Conduct Phase 1 Trial Using QTinno® 5Orexigen® Therapeutics Reports Third Quarter Financial Results 2Orexigen® Therapeutics Reports Third Quarter Financial Results 3Orexigen® Therapeutics Reports Third Quarter Financial Results 4Orexigen® Therapeutics Reports Third Quarter Financial Results 5